Protocols
NYMC-571 Phase II OPEN TO ACCRUAL *
NYMC-571: The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease or Beta Thalassemia Following Myeloablative Conditioning (MAC) and Haploidentical or Matched Unrelated Donor (MUD) Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812)
NYMC-579 Phase II OPEN TO ACCRUAL *
A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs) in Children, Adolescents and Young Adult Recipients
NYMC-580 Phase II OPEN TO ACCRUAL *
A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections with Related Donor CMV Specific Cytotoxic T-Cells (CTLs) in Children, Adolescents and Young Adult Recipients
NYMC-581 Phase II OPEN TO ACCRUAL
A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection with Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Adult Recipients
NYMC-600 Phase II OPEN TO ACCRUAL *
A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated with Either Renal and/or Pulmonary Dysfunction with Either Refractory or Progressive Disease Following Defibrotide Therapy
SYMBIO-BCV-PA02 Phase III OPEN TO ACCRUAL *
A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (allo-HCT)